Stellar Biotechnologies Inc. (SBOTF)

[donfig47]

Stellar Biotechnologies Publishes New Corporate Profile
Mar 13, 2012 8:00:00 AM

PORT HUENEME, CA -- (MARKET WIRE) -- 03/13/12 -- Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) announced today that the Company has published an update to its corporate profile brochure.

The new profile offers introductory insight into Stellar Biotechnologies' business activities, industry-leading KLH operations, and management, as well as a recap of recent milestones. The material is now available for download at www.StellarBiotech.com and at http://bit.ly/xREFRk.

Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH). KLH is an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. Potent, yet proven safe in humans, KLH operates as both a vital component for conjugate vaccines (targeting cancer, autoimmune, and infectious diseases) as well as an antigen for measuring immune status. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Darrell Brookstein
Executive VP, Corporate Development & Finance
[e-mail]